Miromatrix Medical Inc.
MIRODelisted Dec 13, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001527096
Miromatrix Medical Inc. was delisted on Dec 13, 2023; its insiders filed their last Form 4 on Dec 13, 2023; 32 institutions reported holding it in 13F filings for Q3 2023, worth $8.78M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Miromatrix Medical Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Miromatrix Medical Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Erb John L | Director | 0 | Dec 13, 2023 | 0 |
| Buckman Paul | Director | 0 | Dec 13, 2023 | 0 |
| Maag Peter | Director | 0 | Dec 13, 2023 | 0 |
| Burke William P. Mr. | Director | 0 | Dec 13, 2023 | 0 |
| Heine Lisa Wipperman | Director | 0 | Dec 13, 2023 | 0 |
| Ross Jeffrey James | CHIEF EXECUTIVE OFFICER | 0 | Dec 13, 2023 | 0 |
| Douglas James Michael | CHIEF FINANCIAL OFFICER | 0 | Dec 13, 2023 | 0 |
| Barry John Joseph | VICE PRESIDENT OF R&D | 35,485 | Mar 30, 2023 | 0 |
| Niebur Brian | CHIEF FINANCIAL OFFICER | 24,668 | Jan 18, 2022 | 0 |
| Kattungal Laji | VICE PRESIDENT OF QUALITY | 10,000 | Jan 18, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2023 (view filing) | Mar 10 | 20 daysLate | Heine Lisa WippermanDirector | PPurchase | +31.3K | $1.60 | +$50.0K | +63.9%80.2K after | |
| Mar 30, 2023 (view filing) | Mar 10 | 20 daysLate | Burke William P. Mr.Director | PPurchase | +31.3K | $1.60 | +$50.0K | +63.9%80.2K after | |
| Mar 30, 2023 (view filing) | Mar 10 | 20 daysLate | Erb John LDirector | PPurchase | +31.3K | $1.60 | +$50.0K | +125.0%56.3K after | |
| Mar 30, 2023 (view filing) | Mar 10 | 20 daysLate | Maag PeterDirector | PPurchase | +31.3K | $1.60 | +$50.0K | +89.3%66.3K after | |
| Mar 30, 2023 (view filing) | Mar 10 | 20 daysLate | Buckman PaulDirector | PPurchase | +31.3K | $1.60 | +$50.0K | +146.4%52.6K after | |
| Mar 30, 2023 (view filing) | Mar 10 | 20 daysLate | Barry John JosephVICE PRESIDENT OF R&D | PPurchase | +6.25K | $1.60 | +$10.0K | +21.4%35.5K after | |
| Mar 30, 2023 (view filing) | Mar 10 | 20 daysLate | Ross Jeffrey JamesCHIEF EXECUTIVE OFFICER | PPurchase | +31.3K | $1.60 | +$50.0K | +8.6%396.3K after | |
| Mar 30, 2023 (view filing) | Mar 10 | 20 daysLate | Douglas James MichaelCHIEF FINANCIAL OFFICER | PPurchase | +31.3K | $1.60 | +$50.0K | +156.3%51.3K after |